AG
AKBA icon

Artal Group’s Akebia Therapeutics AKBA Stock Holding History

Artal Group’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-574,000
Closed -$7.79M – 136
2020
Q2 		$7.79M Buy
574,000
+149,000
+35% +$1.54M 0.22% 81
2020
Q1 		$3.22M Hold
425,000
– – 0.14% 87
2019
Q4 		$2.69M Hold
425,000
– – 0.1% 89
2019
Q3 		$1.67M Hold
425,000
– – 0.07% 99
2019
Q2 		$2.06M Sell
425,000
-50,000
-11% -$284K 0.08% 94
2019
Q1 		$3.89M Hold
475,000
– – 0.16% 83
2018
Q4 		$2.63M Hold
475,000
– – 0.1% 89
2018
Q3 		$4.19M Hold
475,000
– – 0.11% 79
2018
Q2 		$4.74M Hold
475,000
– – 0.1% 70
2018
Q1 		$4.53M Buy
+475,000
New +$6.64M 0.06% 75

Other funds holding AKBA

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Artal Group's AKBA Position: Q3 2020 in Review

Artal Group sold out of Akebia Therapeutics (AKBA) in Q3 2020, closing a stake of 574,000 shares — an estimated $7.79M sold.

Artal Group first reported a position in AKBA in Q1 2018 and held it in 10 quarters. The position peaked at $7.79M in Q2 2020. 164 funds tracked by Wall St. Rank hold AKBA as of Q3 2020.

  • Artal Group reported no remaining Akebia Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Artal Group sold 574,000 Akebia Therapeutics shares in Q3 2020, an estimated $7.79M.
  • Artal Group first reported a position in Akebia Therapeutics in Q1 2018 and held it in 10 quarters.
  • Artal Group's Akebia Therapeutics position peaked at $7.79M in Q2 2020.
  • 164 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2020.

Based on Artal Group's 13F filing for Q3 2020, filed 13 Nov 2020.